Introduction
We used the Emory Data Warehouse for numerous studies including Adaptive COVID Treatment Trials 1-4 (ACTT1-4). The studies were adaptive, randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of novel therapeutic agents in hospitalized adults diagnosed with COVID-19 (remdesivir, interferon, baricitinib) . These studies were a multicenter trials that were conducted in up to approximately 100 sites globally and led to licensure/approval of remdesivir and baricitinib for severe COVID-19. Emory was the highest enrolling site in the world for all ACTT studies combined. We looked at patients with positive or pending SARS-CoV-2 PCR testing or patients currently in isolation and admitted to EUH, EUHM and ESJH in the past 2 days between March 2020 and April 2021.
CT.gov links below for the 4 studies.